Ardelyx delivered a strong quarter thanks to solid demand for its first FDA-approved product. Here's what investors need to know.
Ardelyx finally received the long-awaited FDA approval for its chronic kidney disease drug.
The company's hopes for approval of a drug to treat chronic kidney disease took a hit.
Morning Markets September E-Mini S&P 500 futures (ESU2 3) this morning are up +0.27%, and Sep Nasdaq 100 E-Mini futures (NQU2 3) are up +0.12%. Stock indexes this morning are moderately higher on mild...
September S&P 500 futures (ESU23) are trending up +0.26% this morning as market participants awaited Federal Reserve Chair Jerome Powell’s speech for further clues on the outlook for interest rates.
Ardelyx (ARDX) delivered earnings and revenue surprises of -18.18% and 12.83%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?